Fulgent Genetics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 4:08 p.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedFulgent Genetics Q3 2026 revenue of $90.4 million beats $86.3 million consensus; GAAP loss $(0.48) per share and non-GAAP loss $(0.09) both beat $(0.65) estimate; annual revenue guidance held at $330-$340 million and non-GAAP loss outlook improved
8-KJuly 30, 2026, 4:09 p.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits